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Abstract 
One of the major challenges facing health professionals is the prevalence of antibiotic resistance. Most Gram-
negative bacteria produce beta-lactamases which are enzymes that in-activate β-lactams. Recent publications 
suggested that extended spectrum beta-lactamase production in E. coli and K. pneumoniae is one of the main 
causes of antimicrobial resistance in penicillins, cephalosporins and some non-beta-lactam antibiotics in Accra. 
This present work sought to determine the resistance profile of antimicrobials to non-ESBL-producing isolates in 
Accra. The 400 K. pneumoniae and E. coli isolates were screened for non-ESBL-producing strains using the 
combined disk method. The minimum inhibition concentration for 17 antibiotics was determined using Vitek 2 
Compact System (bioMérieux, Marcy I’Etoile, France).  Among the 400 total bacterial isolates, 198 (49.5%) 
were non-ESBL producers. Co-resistances to ampicillin (66.7%), piperacillin (59.1%), tetracycline (77.8%) and 
trimethoprim/sulphamethoxazole (68.2%) have been collaborated in this work. The increasing rise in resistance 
to the beta-lactam/beta-lactamase inhibitor combination antibiotics such as amoxicillin/clavulanic acid (13.6%) 
and piperacillin/tazobactam (18.7%) is problematic since they have become the empirical drug of choice for 
treating most infections. The steady increase in resistance to gentamicin (17.2%) as well as the floroquinolones 
such as ciprofloxacin (39.4%) and norfloxacin (34.9%) is alarming. In the absence of ESBLs, cephalosporins 
generally have been effective in treating infections caused by enterobacteria. Nitrofurantoin remains reliable for 
managing non-life threatening urinary tract infections. Amikacin and imipenem continue to be effective third-
line treatment options for Gram-negative bacteria infections.  As antibiotic resistance increases and the 
development of new antimicrobials declines, it is imperative that we use antimicrobials that are still effective 
rationally. Evidence based antibiotic prescriptions and usage as well as regular evaluation of antibiotic resistance 
will help to control the spread of antibiotic resistance in Accra, Ghana.  
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1.0 Introduction 
Infectious diseases account for the major cause of morbidity and mortality in Sub-Sahara Africa and Ghana is no 
exception. The success of antimicrobials against pathogens is one of the remarkable achievements of medical 
science in the past decades (Plotkin and Shnayerson, 2003). Large quantities of assorted antimicrobials are now 
available to developing countries due to economic development and technological advances. This remarkable 
achievement is accompanied by poor practices that promote drug resistance (Beitha, 2008).  
One of the major public health challenges confronting clinicians, microbiologists, drug development 
experts and public health specialists is the prevalence of antibiotic resistance in most known bacterial pathogens. 
Antibiotic resistance in bacteria may be an inherent character of the organism that renders it naturally non-
susceptible to specific antibiotics. Other antibiotic resistances are acquired by means of mutation of the DNA of 
the bacteria or acquisition of resistance-conferring DNA from another source. The genes for drug resistance may 
be located on the bacterial chromosome, plasmid or transposons. Once the resistance genes have developed, they 
can be vertically transferred to the progeny of the parent bacterium during DNA replication. The resistant 
genome can also be horizontally transferred to bacteria of the same species or even different species through the 
process of conjugation, transduction and transformation (Todar, 2008). The problem of antimicrobial resistance 
is compounded by the principles of natural selection. The most common mode of resistant mechanism is 
enzymatic inactivation of the antibiotic (Todar, 2008).  
Recent work published by Hackman and colleagues (2013) suggested that extended spectrum beta-
lactamase production in E. coli and K. pneumoniae is one of the major causes of antimicrobial resistance in 
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penicillins, cephalosporins and some non-beta-lactam drugs in Accra. This present work seeks to determine the 
resistance profile of antimicrobials to non-ESBL-producing isolates in Accra.  
 
2.0 Materials and Methods 
2.1 Materials 
Glycerol broth, blood agar and MacConkey agar were prepared according to manufacturers’ guidelines.  MAST 
IDTM ESβL Detection Disks (Mast Group, UK) were used for ESBL screening and confirmation according to 
CLSI standards.  Vitek 2 Compact System (bioMérieux, Marcy I’Etoile, France) was used to identify the 
isolates, determine minimum inhibition concentration of selected antibiotics and interpret the MICs according to 
CSLI breakpoints.  
 
2.2 Study Sites 
Lactose fermenting bacterial isolates were collected from the Central Laboratory of the Korle Bu Teaching 
Hospital (KBTH) and Advent Clinical Laboratories; both in the Accra Metropolis, Ghana.  
 
2.3 Sample Size 
A sample size of 400 K. pneumoniae and E. coli corresponds with the standard techniques used to calculate the 
minimum sample size based on the expected prevalence and using appropriate levels of precision at 95% 
confidence level.  
 
2.4 Inclusion Criteria 
Non-duplicate pure cultures of K. pneumoniae and E. coli were used in the work. 
 
2.5 Exclusion Criteria 
All isolates not confirmed as K. pneumoniae and E. coli. 
 
2.6 Culturing and Gram Staining of the Bacterial Isolates 
The lactose fermenting bacterial isolates stored in glycerol broth were sub-cultured on blood and MacConkey 
agar and incubated at 35°C for 24 hours. The pure colonies were gram-stained to confirm their Gram negative 
reaction.  
 
2.7 Identification of Bacterial Isolates, Determination of Minimal Inhibition Concentration (MIC) and Antibiotic 
Sensitivity Testing 
The isolates were identified as K. pneumoniae and E. coli based on their Gram stain reaction and biochemical 
reaction characteristics in the ID test cards wells using Vitek 2 system.  The Vitek 2 system (bioMérieux, Marcy 
I’Etoile, France) performs antimicrobial sensitivity testing (AST) based on kinetic analysis of growth data and 
uses the micro-dilution method to determine the therapeutic significance of the MICs of the antibiotics. At the 
end of the incubation cycle, MIC values and their interpretations (susceptible, resistant and indeterminate) were 
generated for each antibiotic.  
Each AST card contains dried antibiotics with a microbiological culture medium in varying concentrations. The 
17 antibiotics used were ampicillin, amoxicillin/clavulanic acid, piperacillin, piperacillin/tazobactam, cefazolin, 
cefoxitin, cefotaxime, ceftazidime, cefepime, imipenem, amikacin, gentamicin, ciprofloxacin, norfloxacin, 
tetracycline, nitrofurantoin, trimethoprim/ sulfamethoxazole.  
 
2.8 Detection of Non-ESBL Phenotype using Combined Disk Method 
MAST IDTM ESβL Detection Disks (Mast Group, UK) were used to screen the ESBL phenotypes. The MAST 
IDTM ESβL Detection Disks comprise of cefpodoxime 30µg disks, cefpodoxime 30µg + clavulanic acid 10µg 
disks; ceftazidime 30µg disks, ceftazidime 30µg + clavulanic acid 10µg disks and cefotaxime 30µg disks, 
cefotaxime 30µg + clavulanic acid 10µg disks.  
Using a pure culture of the test organism, a suspension in distilled water equivalent in density to a McFarland 0.5 
opacity standard was prepared. Using a sterile swab, the suspension was spread uniformly across the surface of 
Mueller-Hinton agar plate. Using a sterile forceps, one of each MAST IDTM ESβL Detection Disks was placed 
onto the inoculated medium ensuring that they were evenly spaced. The plates were incubated aerobically at 35-
37°C for 18 – 20 hours. The diameter of any zones of inhibition that were observed were measured and recorded. 
The zone of inhibition for the cefpodoxime, ceftazidime and cefotaxime was compared to that of the 
cefpodoxime, ceftazidime and cefotaxime plus clavulanic acid combination disks. An increase in zone diameter 
of <5mm in the presence of clavulanic acid from any or all of the sets of MAST IDTM ESβL Detection Disks 
indicates the absence of ESBL in the test organism. 
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2.9 Statistical Analyses 
The data from the work was collated and statistically analysed using using the chi-square test. P values < 0.05 
were considered significant. 
 
3.0 Results 
3.1 Bacterial Isolates 
Of the 400 bacterial isolates collected, 175 (43.7%) were K. pneumoniae and 225 (56.3%) were E. coli.  
3.2 Occurrence of Non-ESBL-producing Phenotypes 
The combined disk synergy method detected 198 (49.5%) of non-ESBL producers among the 400 total bacterial 
isolates of which 46 (26.3%) were K. pneumoniae and 152 (67.5%) were E. coli isolates as shown in table 1. 
        Table 1:                          Distribution of Non-ESBL-Producing Phenotypes 
                                                                            Number (%) 
       
       ESBL Detection Method        K. pneumoniae      E. coli              All Isolates 
                                                                n=175              n=225                 n=400 
       CDM                                              46(26.3)             152(67.5)            198(49.5)              
      
      CDM: Combined Disk Synergy Method 
     
3.3 Antimicrobial Susceptibility among Non-ESBL-producing Isolates 
Of the 198 non-ESBL-producing organisms, 21.2%, 21.7%, 31.8% and 34.8% were susceptible to ampicillin, 
tetracycline, trimethoprim/sulfamethoxazole and piperacillin respectively as indicated in table 2. Approximately 
59% and 72% of the 198 non-ESBL producers were susceptible to amoxicillin/clavulanic acid and 
piperacillin/tazobactam respectively as demonstrated in table 3. Cefazolin, cefotaxime, ceftazidime and cefepime 
recorded susceptibility percentages of 75.3%, 93.9%, 92.9% and 97.0% respectively. Cefoxitin demonstrated 
significant susceptibility of 86.4% to the non-ESBL producers. Of the 198 non-ESBL producers, 99.5%, 98.5%, 
81.3% and 86.9% of imipenem, amikacin, gentamicin and nitrofurantoin were susceptible to the non-ESBL-
producing organisms respectively. Approximately 60% of the non-ESBL producers were susceptible to 
ciprofloxacin and norfloxacin. 
       Table 2: Antimicrobial Susceptibility among Non-ESBL-Producers (n=198) 
                                                                                                                 MIC (µg/ml) 
    Antimicrobial Agent           No. (%) of Susceptible Isolates              MIC50   MIC90 
  Ampicillin                                         42(21.2)                ≤2        ≤2    
  Amoxicillin/Clavulanic acid           116(58.6)                            ≤2   8 
  Piperacillin                                      69(34.8)                ≤4        16      
  Piperacillin/Tazobactam                 142(71.7)               ≤4         8    
 Cefazolin                                          149(75.3)                           ≤4          8              
 Cefoxitin                                          171(86.4)                            ≤4         ≤4 
 Cefotaxime                                      186(93.9)                           ≤1         ≤1     
 Ceftazidime                                     184(92.9)                           ≤1         ≤1 
 Cefepime                                         192(97.0)                           ≤1         ≤1   
 Imipenem                                         197(99.5)                           ≤1         ≤1  
 Amikacin                                         195(98.5)                           ≤2         16 
Gentamicin                                       161(81.3)                            ≤1         ≤1 
 Ciprofloxacin                                  119(60.1)                            ≤0.25    ≤0.25   
 Norfloxacin                                     119(60.1)                          ≤0.5       2 
Tetracycline                                     43(21.7)                             ≤1          ≤1     
Nitrofurantoin                                  172(86.9)              ≤16       32 
Trimethoprim/Sulfamethoxazole      63(31.8)                       ≤20       40 
MIC50: MIC at which 50% of the non-ESBL-phenotypes were susceptible to a particular antimicrobial agent        
 
MIC90: MIC at which 90% of the non-ESBL-phenotypes were susceptible to a particular antimicrobial agent                                 
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3.4 Antimicrobial Resistance among Non-ESBL-producing Isolates 
Of the 198 non-ESBL-producing organisms, 66.7%, 59.1%, 77.8% and 68.2% were resistant to ampicillin, 
piperacillin, tetracycline, and trimethoprim/sulfamethoxazole respectively as indicated in table 3. Approximately 
14%, 19%, 16% and 17% of the non-ESBL producers were resistant to amoxicillin/clavulanic acid, 
piperacillin/tazobactam, cefazolin, and gentamicin respectively. Cefotaxime, ceftazidime, cefepime, imipenem, 
amikacin and nitrofurantoin recorded resistance percentages of less than 5%. Approximately 39% of the non-
ESBL producers were resistance to ciprofloxacin and norfloxacin. 
  Table 3:  Antimicrobial Resistance among Non-ESBL-Producers (n=198)  
                                                                                                                 MIC (µg/ml) 
  Antimicrobial Agent             No. (%) of Resistant Isolates              MIC50     MIC90 
 
Ampicillin                                    132(66.7)                 ≥32           ≥ 32 
Amoxicillin/Clavulanic acid        27(13.6)                       ≥32           ≥ 32 
Piperacillin                                   117(59.1)                 ≥128         ≥ 128       
Piperacillin/Tazobactam              37((18.7)                  ≥128         ≥ 128 
Cefazolin                                      31(15.7)                       ≥64           ≥ 64    
Cefoxitin                                      14((7.1)                   ≥64          ≥ 64 
Cefotaxime                                  4(2.0)                           ≥64           ≥ 64 
Ceftazidime                                 4(2.0)                             32            32 
Cefepime                                     4(2.0)                             32            32 
Imipenem                                    0(0.0)                         -            -        
Amikacin                                     2(1.0)                           ≥64           ≥ 64 
Gentamicin                                  34(17.2)                  ≥16          ≥ 16 
Ciprofloxacin                              78(39.4)                       ≥ 4           ≥ 4 
Norfloxacin                                 78(39.4)          ≥16          ≥16 
Tetracycline                                154(77.8)            ≥16          ≥16 
Nitrofurantoin                             6(3.0)                           256           256  
Trimethoprim/Sulfamethoxazole   135(68.2)                     ≥320        ≥320  
MIC50: MIC at which 50% of the non-ESBL-phenotypes were resistant to a particular antimicrobial agent        
 
MIC90: MIC at which 90% of the non-ESBL-phenotypes were resistant to a particular antimicrobial agent     
 
4.0 Discussion 
Antibiotics are among the most commonly prescribed drugs in hospitals and studies on their resistance patterns 
ensure quality healthcare. Antibiotics are widely and inappropriately used in Ghana resulting to antibiotic 
resistance. Newman and colleagues (2006) who studied bacterial isolates from various clinical specimens in 
Ghana, recorded high resistance rates for tetracycline, co-trimoxazole, ampicillin  and chloramphenicol. Though 
the work of Newman and colleagues (2006) did not specify the ESBL phenotypes of the bacterial isolates, their 
findings were consistent with this present study with high resistances of non-ESBL-producing bacterial isolates 
to ampicillin, tetracycline and trimethoprim/sulphamethoxazole. 
In Zimbabwe (Mbanga et al., 2010), the high resistance to ampicillin, co-trimoxazole and 
trimethoprim/sulphamethoxazole reported correlate to this study. Also, the findings of a study in Ethiopia 
(Kibret and Abera, 2011) with high resistance rate to tetracycline are confirmed in this study. It was reported in 
Nigeria that Gram-negative isolates showed high resistance to ampicillin (90%) and co-trimoxazole (85%) 
(Clarence et al., 2007) which were slightly higher than rates recorded in this study. On the other hand, lower rate 
of resistance was observed for ceftriazone (a third generation cephalosporin) and amikacin in Ghana by Newman 
and colleagues in 2006. This is consistent with this study with non-ESBL-producers resistant rates of 2% to 
cefotaxime, ceftazidime and cefepime (which are third generation cephalosporins) and 1% for amikacin. 
However, there was increased resistant rate of 39.4% to ciprofloxacin and norfloxacin.  
The steady rise in resistance of bacterial isolates to the fluoroquinolones such as ciprofloxacin and 
norfloxacin is alarming as cautioned by Newman and Seidu (2002). The rise in resistance to fluoroquinolones 
may be due to the ease with which mutations in the DNA gyrase are transferred to other fluoroquinolones 
(Nankanishi et al., 1999). This may explain why both ciprofloxacin and norfloxacin have similar high resistance 
rates of 39.4% as observed in this study.  
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The observed increase in resistance in non-ESBL producers to the beta-lactam/beta-lactamase inhibitor 
combination antimicrobials such as amoxicillin/clavulanic acid and piperacillin/tazobactam is worrying since 
these beta-lactam/beta-lactamase inhibitor combination antibiotics have become the empirical drug of choice for 
some clinicians for treating infectious diseases in Ghana. As antibiotic resistance increases and the development 
of new antimicrobials declines, it would seem prudent to take the caution of Kimang’a (2012) seriously. 
Nitrofurantoin continues to be effective against K. pneumoniae and E. coli infections especially in non-life 
threatening urinary tract infections. Considering the resistant rate of 1% and 0% for amikacin and imipenem 
respectively, it is appropriate to reserve these two antibiotics for third-line treatment options.   
5.0 Conclusion 
Co-resistances to ampicillin (66.7%), piperacillin (59.1%), tetracycline (77.8%) and 
trimethoprim/sulphamethoxazole (68.2%) have been collaborated in this work. The increasing rise in resistance 
to the beta-lactam/beta-lactamase inhibitor combination antibiotics such as amoxicillin/clavulanic acid (13.6%) 
and piperacillin/tazobactam (18.7%) is very worrying. The steady increase in resistance to gentamicin (17.2%) as 
well as the floroquinolones such as ciprofloxacin (39.4%) and norfloxacin (34.9%) is alarming. In the absence of 
ESBLs, cephalosporins have generally been effective in treating infections caused by enterobacteria. 
Nitrofurantoin remains reliable for managing non-life threatening urinary tract infections. Amikacin and 
imipenem continue to be effective non first-line treatment options for Gram-negative bacteria infections.  
Evidence based guidelines and clinical practices and systematic implementation of antimicrobial stewardship 
programs should be encouraged to improve antimicrobial use.  
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